Cerebrospinal Fluid Tau and β-Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915

Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach

DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012

An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βApp 717 ) Mutants

Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”

The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 719

Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701

The 14-3-3 Brain Protein in Cerebrospinal Fluid as a Marker for Transmissible Spongiform Encephalopathies

Hsich, G. E., Kenney, K., Gibbs, C. J., Lee, K. H., & Harrington, M. G. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351303 · Cited by 657

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573

Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

Vandermeeren, M., Mercken, M. H., Vanmechelen, E., Six, J., VOORDE, A. V. D., Martin, J., & Cras, P. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 496

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863

Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance

Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896

APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging

Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease

Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835

MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers

Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., Thompson, P. M., Jack, C. R., Weiner, M. W., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awp007 · Cited by 679

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M. N., Scheltens, P., Tariska, P., & Winblad, B. G. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 634

Focal cortical presentations of Alzheimer's disease

Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., & Hodges, J. R. (2007) · Brain · doi:10.1093/brain/awm213 · Cited by 581

BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer’s Disease

Gaser, C., Franke, K., Klöppel, S., Koutsouleris, N., Sauer, H., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067346 · Cited by 555

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 473

Alzheimer’s Disease

de Paula, V. D. J. R., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_14 · Cited by 466

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease

Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434

Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease

Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425

Diversity and Disparity in Dementia: The Impact of Ethnoracial Differences in Alzheimer Disease

Chin, A. L., Negash, S., & Hamilton, R. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318211c6c9 · Cited by 416

MRI and CSF biomarkers in normal, MCI, and AD subjects

Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79fb · Cited by 406

CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease

Siderowf, A. D., Xie, S. X., Hurtig, H. I., Weintraub, D. A., Duda, J. E., Chen‐Plotkin, A. S., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., & Clark, C. N. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 386

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

Shaw, L. M. J., Korecka, M., Clark, C. M., Lee, V. M. ‐., & Trojanowski, J. Q. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2176 · Cited by 348

Alzheimer's Disease and Mild Cognitive Impairment

Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 335

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

Initiative, T. A. D. N., Shaw, L. M. J., Vanderstichele, H., Knapik-Czajka, M. E., Figurski, M., Coart, E., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 301

Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues

Brambilla, D., Droumaguet, B. L., Nicolas, J., Hashemi, S. H., Wu, L., Moghimi, S. M., Couvreur, P., & Andrieux, K. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.03.008 · Cited by 302

CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment

Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 275

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

Engelborghs, S., de Vreese, K., de Casteele, T. V., Vanderstichele, H., Everbroeck, B. V., Cras, P. P., Martin, J., Vanmechelen, E., & Deyn, P. P. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.016 · Cited by 268

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers

Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253

Alzheimer Disease

Apostolova, L. G. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000307 · Cited by 277

MRI and CSF biomarkers in normal, MCI, and AD subjects

Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79e5 · Cited by 251

Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention

Iqbal, K., & Grundke, I. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00225.x · Cited by 243

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease

Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M. J., Perrin, R. J., Arnold, S. E., Grossman, M., Xiong, C., Craig‐Schapiro, R., Clark, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318266fa70 · Cited by 237

Early diagnosis of Alzheimer’s disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts

Rossini, P. M., Iorio, R. D., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M., Bruni, A. C., Cappa, S. F., Escudero, J., Fraga, F. J., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.03.003 · Cited by 257

Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans

Hua, X., Hibar, D. P., Lee, S., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.033 · Cited by 234

The Role of Biomarkers in Clinical Trials for Alzheimer Disease

Thal, L. J., Kantarci, K., Reiman, E. M., Klunk, W. E., Weiner, M. W., Zetterberg, H., Galasko, D., Praticò, D., Griffin, S. T., Schenk, D., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000191420.61260.a8 · Cited by 235

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease

Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228

Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223

Evidence for Ordering of Alzheimer Disease Biomarkers

Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 225

Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease

Podlesniy, P., Figueiro‐Silva, J., Llado, A., Antonell, A., Sanchez‐Valle, R., Alcolea, D., Lleo, A., Molinuevo, J. L., Serra, N., & Trullas, R. (2013) · Annals of Neurology · doi:10.1002/ana.23955 · Cited by 219

Biomarkers of Alzheimer's disease

Craig‐Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.003 · Cited by 228

CSF biomarkers in frontotemporal lobar degeneration with known pathology

Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311445.21321.fc · Cited by 216

Fluid Biomarkers in Alzheimer Disease

Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208

Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play

Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211

3D-Deep Learning Based Automatic Diagnosis of Alzheimer’s Disease with Joint MMSE Prediction Using Resting-State fMRI

Duc, N. T., Ryu, S., Qureshi, M. N. I., Choi, M., Lee, K. H., & Lee, B. (2019) · Neuroinformatics · doi:10.1007/s12021-019-09419-w · Cited by 210

Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects

Castaño, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A., & Beach, T. G. (2006) · Neurological Research · doi:10.1179/016164106x98035 · Cited by 201

Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment

Hu, W. T., Chen‐Plotkin, A. S., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M. J., Pickering, E. H., Kühn, M., Chen, Y., McCluskey, L. F., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0667-0 · Cited by 196

Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias

de Souza, L. C., Lamari, F., Belliard, S., Jardel, C., Houillier, C., Paz, R. D., Dubois, B., & Sarazin, M. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.207183 · Cited by 196

Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease

Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N. R., & Lee, K. H. (2006) · Annals of Neurology · doi:10.1002/ana.21038 · Cited by 185

CSF biomarkers cutoffs: The importance of coincident neuropathological diseases

Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182

Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition

Leow, A. D., Yanovsky, I., Parikshak, N., Hua, X., Lee, S., Toga, A. W., Jack, C. R., Bernstein, M. A., Britson, P. J., Gunter, J. L., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.004 · Cited by 180

PET amyloid-beta imaging in preclinical Alzheimer's disease

Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 188

Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

Diniz, B. S., Pinto, J. A., & Forlenza, O. V. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701535502 · Cited by 173

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

van Harten, A. C., Kester, M. I., Visser, P. J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.086 · Cited by 168

Quantitative analysis of amyloid β peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry

Oe, T., Ackermann, B. L., Inoue, K., Berna, M. J., Garner, C. O., Gelfanova, V., Dean, R. A., Siemers, E., Holtzman, D. M., Farlow, M. R., et al. (2006) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2787 · Cited by 166

Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25–35

Kaminsky, Y. G., Marlatt, M. W., Smith, M. A., & Kosenko, E. A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.005 · Cited by 171

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161

Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results

Baudron, C. R., Krolak‐Salmon, P., Quadrio, I., Mégraud, F., & Salles, N. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.021 · Cited by 152

Stem Cell-Derived Exosomes: a New Strategy of Neurodegenerative Disease Treatment

Hosseini, N. F., Sheykhhasan, M., Asl, S. S., & Najafi, R. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02324-x · Cited by 155

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149

The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort

Caroli, A., & Frisoni, G. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.024 · Cited by 150

Diagnosis and biomarkers of predementia in Alzheimer's disease

Forlenza, O. V., Diniz, B. S., & Gattaz, W. F. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-89 · Cited by 160

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study

Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Paricio, M., Lorites, J., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12137 · Cited by 143

CSF biomarker levels in early and late onset Alzheimer's disease

Bouwman, F. H., Schoonenboom, N. S. M., Verwey, N. A., van Elk, E. J., Kok, A., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.02.007 · Cited by 150

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D. P., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W. R., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140

Biomarkers for Alzheimer's disease therapeutic trials

Hampel, H. J., Wilcock, G. K., Andrieu, S., Aisen, P. S. S., Blennow, K., Broich, K., Carrillo, M. C., Fox, N. C., Frisoni, G. B., Isaac, M., et al. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.11.005 · Cited by 140

3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects

Apostolova, L. G., Hwang, K., Andrawis, J. P., Green, A. E., Babakchanian, S., Morra, J. H., Cummings, J. L., Toga, A. W., Trojanowski, J. Q., Shaw, L. M. J., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.003 · Cited by 144

Dementia risk and prevention by targeting modifiable vascular risk factors

Tariq, S., & Barber, P. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14132 · Cited by 140

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study

Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S., Soininen, H., Maetzler, W., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.12.006 · Cited by 133

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Mattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.034 · Cited by 136

Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer’s Disease

Jiang, L., Dong, H., Cao, H., Ji, X., Luan, S., & Liu, J. (2019) · Medical Science Monitor · doi:10.12659/msm.914027 · Cited by 130

Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies

Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130

Tau as a Biomarker of Neurodegenerative Diseases

Schraen‐Maschke, S., Sergeant, N., Dhaenens, C., Bombois, S., Deramecourt, V., Caillet‐Boudin, M., Pasquier, F., Maurage, C., Sablonnière, B., Vanmechelen, E., et al. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.4.363 · Cited by 129

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies

Mitchell, A. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.167791 · Cited by 124

Biomarkers in Alzheimer's disease drug development

Cummings, J. L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 122

Future Therapeutic Perspectives into the Alzheimer’s Disease Targeting the Oxidative Stress Hypothesis

Teixeira, J. P., de Castro, A. A., Soares, F. V., da Cunha, E. F. F., & Ramalho, T. C. (2019) · Molecules · doi:10.3390/molecules24234410 · Cited by 124

Current therapeutic targets for the treatment of Alzheimer’s disease

Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123

Harmonized diagnostic criteria for Alzheimer's disease: recommendations

Morris, J. C., Blennow, K., Froelich, L., Nordberg, A. K., Soininen, H. S., Waldemar, G., Wahlund, L., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 122

Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls

Chou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117

Spatial patterns of brain amyloid- burden and atrophy rate associations in mild cognitive impairment

Tosun, D., Schuff, N. W., Mathis, C. A., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2011) · Brain · doi:10.1093/brain/awr044 · Cited by 122

Upcoming Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Fagan, A. M., & Perrin, R. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.42 · Cited by 118

Comparison of Cerebrospinal Fluid Levels of Tau and Aβ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms

Irwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L.-S., Van Deerlin, V., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.26 · Cited by 116

Brain Ventricular Volume and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

Ott, B. R., Initiative, T. A. D. N., Cohen, R. A., Gongvatana, A., Okonkwo, O. C., Johanson, C. E., Stopa, E. G., Donahue, J. E., & Silverberg, G. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1406 · Cited by 117

Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment

Pesaresi, M., Lovati, C., Bertora, P., Mailland, E., Galimberti, D., Scarpini, E. A., Quadri, P., Forloni, G., & Mariani, C. B. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.004 · Cited by 111

Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease

Roher, A. E., Maarouf, C. L., Sue, L. I., Hu, Y., Wilson, J. R., & Beach, T. G. (2009) · Biomarkers · doi:10.3109/13547500903108423 · Cited by 111

Dementia syndromes: evaluation and treatment

Scott, K. R., & Barrett, A. M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.4.407 · Cited by 113

CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI

Herukka, S., Helisalmi, S., Hallikainen, M., Tervo, S., Soininen, H. S., & Pirttilä, T. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.001 · Cited by 113

CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease

Schoonenboom, N. S. M., van der Flier, W. M., Blankenstein, M. A., Bouwman, F. H., van Kamp, G. J., Barkhof, F., & Scheltens, P. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.018 · Cited by 107

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease

van der Vlies, A. E., Verwey, N. A., Bouwman, F. H., Blankenstein, M. A., Klein, M., Scheltens, P., & van der Flier, W. M. (2009) · Neurology · doi:10.1212/01.wnl.0000345014.48839.71 · Cited by 106

A Blood Gene Expression Marker of Early Alzheimer's Disease

Lunnon, K., Sattlecker, M., Furney, S. J., Coppola, G., Simmons, A., Proitsi, P., Lupton, M. K., Lourdusamy, A., Johnston, C., Soininen, H. S., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121363 · Cited by 104

CSF biomarker changes precede symptom onset of mild cognitive impairment

Moghekar, A., Li, S., Lu, Y., Li, M., Wang, M.-C., Albert, M., O’Brien, R., & For the BIOCARD Research Team (2013) · Neurology · doi:10.1212/01.wnl.0000435558.98447.17 · Cited by 103

Comparison of Electrodiagnostic Abnormalities and Criteria in a Cohort of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Magda, P., Latov, N., Brannagan, T. H., Weimer, L. H., Chin, R. L., & Sander, H. W. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1755 · Cited by 100

Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients

Babiloni, C., Percio, C. D., Bordet, R., Bourriez, J., Bentivoglio, M., Payoux, P., Derambure, P., Dix, S. L., Infarinato, F., Lizio, R., et al. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.09.017 · Cited by 101

Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia

de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.7.755 · Cited by 98

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study

Tosun, D., Schuff, N. W., Truran‐Sacrey, D., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Peterson, R., & Weiner, M. W. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.030 · Cited by 99

Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients

Di Domenico, F., Pupo, G., Giraldo, E., Badìa, M.-C., Monllor, P., Lloret, A., Eugenia Schininà, M., Giorgi, A., Cini, C., Tramutola, A., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.004 · Cited by 97

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease

Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93

The comparison of cerebrospinal fluid levels of tau protein and β-amyloid peptide1-42 in the patients with Alzheimer's disease and those with vascular dementia

Yi, L., 张中兴, 吕路线, 郝伟, & 丁新生 (2004) · doi:10.3760/j:issn:1006-7884.2004.04.007

Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656

CSF tau protein andβ‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population

Kapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 80

Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice

Parnetti, L., Lanari, A., Saggese, E., Spaccatini, C., & Gallai, V. (2003) · Neurological Sciences · doi:10.1007/s10072-003-0129-8 · Cited by 21

Simultaneous assay of CSF levels of tau and Aβ1-42 to the diagnosis of Alzheimer's disease

Yi, W. (2003) · Zhongguo shenjing kexue zazhi